Review of quetiapine and its clinical applications in schizophrenia

@article{Kasper2000ReviewOQ,
  title={Review of quetiapine and its clinical applications in schizophrenia},
  author={Siegfried Kasper and Franz M{\"u}ller-Spahn},
  journal={Expert Opinion on Pharmacotherapy},
  year={2000},
  volume={1},
  pages={783 - 801}
}
Preclinical studies have shown that quetiapine (Seroquel™, AstraZeneca) is an atypical antipsychotic with many similarities to clozapine. Both placebo-controlled and comparative studies in patients with schizophrenia have demonstrated that quetiapine has long-term efficacy in both positive and negative domains, as well as beneficial effects on affective and cognitive symptoms. Comparative clinical studies confirm that quetiapine is at least as effective as the standard antipsychotics… 
Quetiapine: efficacy and tolerability in schizophrenia
TLDR
The combination of efficacy comparable to other antipsychotic agents, with an acceptable side effect and tolerability profile, provides support for the use of quetiapine as a first-line antipsychotics agent in the long-term treatment of schizophrenia.
Quetiapine. A review of its use in the management of schizophrenia.
TLDR
Overall, quetiapine has an excellent risk/benefit profile and is a suitable first-line option for the treatment of schizophrenia, and has benefits in improving cognitive deficits, affective symptoms and aggression/hostility.
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
TLDR
Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment and was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol.
Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study
  • J. Hellewell
  • Medicine
    International journal of psychiatry in clinical practice
  • 2007
TLDR
This study provides further evidence for the utility and tolerability of quetiapine, in patients with schizophrenia who had been switched from a previous antipsychotic, following problems with efficacy or tolerability.
Quetiapine: efficacy, tolerability and safety in schizophrenia
TLDR
The purpose of this article is to critically review the current literature on quetiapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of schizophrenia.
Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics
TLDR
Results indicate that switching to quetiapine was clinically beneficial for patients with poor efficacy or intolerable side effects on their previous antipsychotic medication.
Quetiapine – efficacy in different domains
  • T. Sharma
  • Medicine, Psychology
    European Neuropsychopharmacology
  • 2001
TLDR
Results of well-controlled, double-blind, randomised studies show quetiapine to significantly improve cognitive function compared with treatment with haloperidol, making it well suited for use as first-line therapy.
Quetiapine : A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease
TLDR
If dosage reduction of antiparkinsonian therapy does not alleviate psychotic symptoms in patients with Parkinson's disease, quetiapine may offer an effective alternative to other atypical antipsychotic agents, without compromising motor function.
Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics
TLDR
The results from clinical trials suggest that atypical agents improve negative and affective symptoms, and cognitive functioning more than typical antipsychotics, but that the pattern of effects on these domains, as well as on suicidality, appears to differ.
The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia
TLDR
The results indicate that long-term weight changes with quetiapine monotherapy are minimal and potentially beneficial, and do not appear to raise the medical concerns associated with some other atypical agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 107 REFERENCES
Quetiapine : A Review of its Use in Schizophrenia.
TLDR
Quetiapine should provide a valuable alternative to classical antipsychotic agents in the short term treatment of patients with schizophrenia and its long term effectiveness, position relative to other atypical antipsychotics agents and efficacy in refractory schizophrenia remain to be fully determined.
Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic.
  • P. Meats
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 1997
TLDR
The preclinical studies predict a low risk of extrapyramidal symptoms, and this is borne out in clinical trials in patients with relapses of moderate or severe schizophrenia, and quetiapine offers the clinician a significant advance over standard antipsychotic drugs.
A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
TLDR
It is suggested that quetiapine may make a valuable contribution to the management of patients with a history of partial response to conventional antipsychotics, as shown in the results of this international, multicentre, double‐blind study.
Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
TLDR
Quetiapine is an effective antipsychotic with a favorable safety profile and the optimum dose is probably greater than 250 mg/d, which is well tolerated and did not induce extrapyramidal symptoms, sustained elevations of prolactin, or clinically significant changes in hematologic parameters.
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
TLDR
The quetiapine group had a lower incidence of adverse events than the chlorpromazine group, and a low incidence of treatment‐emergent extrapyramidal symptoms, which support the preclinical profile of quetuapine as an atypical antipsychotic agent.
The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia
TLDR
The results indicate that long-term weight changes with quetiapine monotherapy are minimal and potentially beneficial, and do not appear to raise the medical concerns associated with some other atypical agents.
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Olanzapine and risperidone, both second-generation antipsychotic agents, represent two different pharmacologic strategies. Although they share some in vitro properties, they differ by virtue of their
Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.
TLDR
Quetiapine was well tolerated in a nonrandomized study of elderly patients and was associated with improvement in symptoms, including significant improvement in Simpson-Angus Scale total score and CGI-Severity of Illness scores.
A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia
TLDR
Quetiapine is an effective and well tolerated antipsychotic of comparable efficacy to haloperidol and lacks the latter compound's effect on prolactin and EPS.
Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
TLDR
Quetiapine is well tolerated and clinically effective in the treatment of schizophrenia and both superior to placebo and comparable to haloperidol in reducing positive symptoms at doses ranging from 150 to 750 mg/day and in reducing negative symptoms at a dose of 300mg/day.
...
1
2
3
4
5
...